samedan logo

home > ict > autumn 2019 > the formula for success
International Clinical Trials

The Formula for Success

In early 2019, the FDA released a revised draft guidance for rare disease clinical trials (1). The guidance, updated from a 2015 version, provided clarification in certain areas such as natural history studies, evaluation and validation of biomarkers as surrogate endpoints, evaluation of novel drug compounds, drug manufacturing, and safety. Well-received, the 2019 guidance is intended to encourage sponsors to tackle the complex issues associated with rare disease research proactively so that research can be conducted more effectively and efficiently.

Main Challenges

Rare diseases affect a small population of people who are dispersed across the world, and it makes country and site selection, clinical trial recruitment, and long-term retention particularly complex. Furthermore, many rare diseases are difficult to diagnose, and, as a result, a misdiagnosis can occur. Although more rare diseases are being identified through recent medical advancements and development of new diagnostic techniques, it typically takes time for the diagnostic and screening standards to be established. Obtaining an accurate diagnosis is often one of the first obstacles to overcome.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the authors

Dr Pavle Vukojevic, Chief Medical Officer, joined Pharm-Olam in 1997 and supports clinical operations with protocol development, therapeutic training, patient safety issues, study management, and feasibility support. Pavle received his MD in 1988 from the University of Belgrade, Serbia, and also has a Master’s degree in Immunology and a specialisation in Internal Medicine. He is a former President of the Association of Clinical Research Professional’s Serbia Chapter and was an assistant professor at the Medical School University of Belgrade for internal medicine/ rheumatology. He is the author of ‘Conducting Clinical Trials in Europe: An Insider’s Analysis’, written for Insight Pharma Reports.

Dr Milan Marinkov has been with Pharm- Olam since 2013 and is currently Senior Medical Director. Milan is the leading medic and head of the Rare and Orphan Disease Center of Excellence, responsible for the evaluation, medical management, and conduct of multiple global studies within the rare disease study portfolio. He received his medical degree from the University of Novi Sad, Serbia, and is currently engaged in PhD studies.

Dr Jovana Vlajkovic-Josic, project management professional, joined Pharm-Olam in 2004 and is currently Associate Medical Director with experience in both medical and project management departments. As a licensed physician with postgraduate immunology training, Jovana’s orphan clinical trial experience includes a broad range of indications and phases.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

Industry Events

SCOPE Summit for Clinical Ops Executives

18-21 February 2020, Hyatt Regency, Orlando, Florida, US

Celebrating its 11th successful year, SCOPE Summit 2020 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 20 different conferences, 3 plenary keynote sessions, the annual Participant Engagement Awards, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement